trial · primary record
Patritumab Deruxtecan (Fixed dose)
Non-Small Cell Lung Cancer Metastatic
| Phase | Phase 2 |
|---|---|
| Status | ACTIVE |
| Sponsor | Unknown |
| Enrolment | 277 |
| Primary completion | 2027-01-04 |
| Primary endpoint | Objective Response Rate (ORR) as Assessed by Blinded Independent Central Review (BICR) |
| Registry ID | NCT04619004 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-02T15:46:35.189Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT04619004
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.